Programme Thesis
The NIH SBIR (R43/R44) program funds U.S. small businesses to develop and commercialize innovative technologies that address biomedical research and health challenges, including addiction. It exists to bridge the gap between academic discovery and marketable products, stimulating the U.S. economy while improving public health outcomes.
Selection Criteria
1. Overall Impact (1-5): likelihood the project will exert a sustained, powerful influence on the research field(s) involved. 2. Significance: does the project address an important problem or critical barrier to progress? 3. Investigator(s): are the PD/PIs, collaborators, and other researchers well-suited? 4. Innovation: novel concepts, approaches, or technologies? 5. Approach: are the strategies, methods, and analyses well-reasoned and appropriate? 6. Environment: does the scientific environment contribute to success? Additional review criteria include commercial potential, feasibility, and for Phase II, commercialization plan. Scoring: 1 (exceptional) to 9 (poor); overall score determines funding priority.
Past Winners / Cohort Profiles
Typical SBIR winners are U.S.-based small businesses (≤500 employees) with a strong scientific founder or academic partner. Examples include biotech startups developing novel therapeutics, diagnostics, or medical devices (e.g., a company creating a digital therapeutic for substance use disorder). Named examples from NIH SBIR: 'Aim for Behavior' (digital health), 'Pear Therapeutics' (prescription digital therapeutics), 'Cognoa' (AI for autism diagnosis). Profiles often include a mix of PhD/MD scientists and business co-founders, with prior seed funding or academic proof-of-concept.
Ideal Candidate Fingerprint
A U.S.-registered small business (e.g., LLC or C-corp) with a scientific founder holding a PhD or MD, complemented by a business co-founder. The company should have a clear, commercially viable technology (e.g., a software platform, diagnostic tool, or therapeutic) with strong preliminary data, a defined target market (e.g., addiction treatment clinics), and a plan for regulatory approval (e.g., FDA). The PI must be a U.S. citizen or permanent resident, or the company must be majority-owned by such individuals.
Recommended Framing
Eniola should partner with a U.S.-based small business (e.g., a digital health startup focused on addiction) or form a U.S. subsidiary (e.g., 'CCT Therapeutics Inc.' in Delaware) to qualify. The strongest angle is to frame the CCT model and IMPRINT platform as a commercializable, AI-driven screening tool for addiction liability, targeting pharmaceutical companies and clinics. Emphasize the validated Bayesian model (85.8% reduction in encoding probability), the provisional patent, and the potential to reduce opioid relapse rates, aligning with NIH's HEAL Initiative priorities. Eniola's role would be as a subcontractor or scientific advisor, leveraging his unique computational pharmacology expertise and African perspective to address a global health challenge.
Watch Out
Eligibility: SBIR requires the applicant to be a U.S. small business (≥51% owned by U.S. citizens/permanent residents). Eniola is a Nigerian citizen residing in Lagos, so he cannot be the PI or majority owner unless he forms a U.S. entity and obtains a visa (e.g., O-1 or E-2). The grant does not fund independent researchers directly; a U.S. company must submit. Additionally, the deadline (April 2027) is far off, but Eniola's lack of a PhD or U.S. affiliation may weaken the 'Investigator' score. He should secure a U.S.-based collaborator with a strong track record in addiction research or SBIR awards.